Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aptose Biosciences, Inc. (APTO : NSDQ)
 
 • Company Description   
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.

Number of Employees: 42

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.07 Daily Weekly Monthly
20 Day Moving Average: 455,926 shares
Shares Outstanding: 92.23 (millions)
Market Capitalization: $98.68 (millions)
Beta: 1.50
52 Week High: $5.78
52 Week Low: $0.90
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.96% 1.88%
12 Week -11.57% -0.62%
Year To Date -20.74% -3.17%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
251 CONSUMERS ROAD SUITE 1105
-
TORONTO,A6 M2J 4R3
CAN
ph: 64-7479-9828
fax: 905-234-2120
ir@aptose.com http://www.aptose.com
 
 • General Corporate Information   
Officers
William G. Rice - President; Chief Executive Officer and Chairman
Jotin Marango - Senior Vice President and Chief Financial Officer
Denis R. Burger - Director
Carol G. Ashe - Director
Caroline Loewy - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03835T200
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 92.23
Most Recent Split Date: 10.00 (0.08:1)
Beta: 1.50
Market Capitalization: $98.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.51
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 33.33%
vs. Previous Quarter: 55.56%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -74.28
12/31/21 - -70.56
09/30/21 - -53.69
ROA
03/31/22 - -67.62
12/31/21 - -65.17
09/30/21 - -50.11
Current Ratio
03/31/22 - 9.83
12/31/21 - 10.00
09/30/21 - 11.60
Quick Ratio
03/31/22 - 9.83
12/31/21 - 10.00
09/30/21 - 11.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.71
12/31/21 - 0.81
09/30/21 - 1.00
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©